<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04967508</url>
  </required_header>
  <id_info>
    <org_study_id>SB17-3001</org_study_id>
    <nct_id>NCT04967508</nct_id>
  </id_info>
  <brief_title>A Study to Compare SB17 (Proposed Ustekinumab Biosimilar) to Stelara® in Subject With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Phase III, Randomised, Double-blind, Multicentre Clinical Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Immunogenicity of SB17 (Proposed Ustekinumab Biosimilar) Compared to Stelara® in Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Samsung Bioepis Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Samsung Bioepis Co., Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomised, double-blind, multicentre clinical study to evaluate the efficacy,&#xD;
      safety, tolerability, PK, and immunogenicity of SB17 compared to Stelara® in subjects with&#xD;
      moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be randomised in a 1:1 ratio to receive either SB17 or Stelara® via&#xD;
      subcutaneous injection. At Week 28, subjects receiving Stelara® will be randomised again in a&#xD;
      1:1 ratio to either continue on Stelara® or be transitioned to SB17. Investigational products&#xD;
      (IPs) (SB17 or Stelara®) will be administered at Week 0, 4, and then every 12 weeks up to&#xD;
      Week 40, and the last assessment will be done at Week 52.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 6, 2021</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change from baseline in PASI at Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">464</enrollment>
  <condition>Psoriasis</condition>
  <condition>Moderate to Severe Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>SB17 (Proposed Ustekinumab Biosimilar)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Stelara® (Ustekinumab)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Stelara® (Ustekinumab)</intervention_name>
    <description>Subjects randomised into Stelara® group will receive Stelara® (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.</description>
    <arm_group_label>Stelara® (Ustekinumab)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SB17 (Proposed Ustekinumab Biosimilar)</intervention_name>
    <description>Subjects randomised into SB17 group will receive SB17 (45 mg) via subcutaneous injection at Week 0, 4, and then every 12 weeks up to Week 40.&#xD;
Starting at Week 28, subjects transited from Stelara® to SB17 will receive SB17 via subcutaneous injection.</description>
    <arm_group_label>SB17 (Proposed Ustekinumab Biosimilar)</arm_group_label>
    <arm_group_label>Stelara® (Ustekinumab)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged 18 years or older at Screening.&#xD;
&#xD;
          -  Have plaque psoriasis diagnosed at least 6 months, with or without psoriatic&#xD;
             arthritis.&#xD;
&#xD;
          -  Have plaque psoriasis with the involvement and severity of total affected BSA ≥ 10%,&#xD;
             PASI score of ≥ 12 and PGA score of ≥ 3 (moderate).&#xD;
&#xD;
          -  Considered to be a candidate for phototherapy or systemic therapy for psoriasis&#xD;
&#xD;
          -  Less than 95 kg of body weight.&#xD;
&#xD;
          -  Adequate hematological, renal and hepatic function by central lab.&#xD;
&#xD;
          -  Non-childbearing potential female, or childbearing potential female subjects or male&#xD;
             subjects with their partners who agree to use at least two forms of appropriate&#xD;
             contraception method from Screening until 15 weeks after the last dose of IP.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have nonplaque forms of psoriasis, including erythrodermic, pustular, guttate, or&#xD;
             drug-induced psoriasis.&#xD;
&#xD;
          -  Have other skin disease than psoriasis that requires topical or systemic&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Prior biologic use as any TNF inhibitors within the previous 6 months; any IL-12 or&#xD;
             IL-23 inhibitor biologics, IL-17 inhibitor, rituximab, or integrin inhibitor biologics&#xD;
             at any time; or other biologics within the longer of either 5 half-lives or 3 months&#xD;
             prior to randomisation.&#xD;
&#xD;
          -  Known allergic reactions or hypersensitivity to ustekinumab or to any ingredients of&#xD;
             Stelara® or SB17&#xD;
&#xD;
          -  History of exfoliative dermatitis, reversible posterior leukoencephalopathy syndrome,&#xD;
             facial palsy, allergic alveolitis, or non-infectious pneumonia.&#xD;
&#xD;
          -  Have received phototherapy or conventional systemic therapy for psoriasis within 4&#xD;
             weeks prior to Randomisation.&#xD;
&#xD;
          -  Have received topical therapy for psoriasis within 2 weeks prior to Randomisation.&#xD;
&#xD;
          -  Women who are pregnant or nursing at Screening, or men and women planning pregnancy&#xD;
             during the study period and until 15 weeks after the last dose of IP.&#xD;
&#xD;
          -  Have received a live or live attenuated viral vaccine or a live bacterial vaccine&#xD;
             within 4 weeks (for BCG, 12 months) prior to Randomisation.&#xD;
&#xD;
          -  Have active or latent tuberculosis.&#xD;
&#xD;
          -  History of ongoing infection or a positive test of HBV, HCV, or HIV infection&#xD;
&#xD;
          -  History of sepsis, chronic or recurrent infection&#xD;
&#xD;
          -  History of malignancy within the last 5 years&#xD;
&#xD;
          -  History of lymphoproliferative disease or leukemia&#xD;
&#xD;
          -  History of myocardial infarction, NYHA III/IV congestive heart failure, or stroke&#xD;
             within 12 months&#xD;
&#xD;
          -  Have uncontrolled hypertension or diabetes&#xD;
&#xD;
          -  History of uncontrolled psychiatric disorders or risk of suicide&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samsung Bioepis</last_name>
    <phone>+82 32 728 0371</phone>
    <email>sbregistry@samsung.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>SB Investigative Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>SB investigative site</name>
      <address>
        <city>Vilnius</city>
        <country>Lithuania</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Estonia</country>
    <country>Lithuania</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 8, 2021</study_first_submitted>
  <study_first_submitted_qc>July 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 19, 2021</study_first_posted>
  <last_update_submitted>July 8, 2021</last_update_submitted>
  <last_update_submitted_qc>July 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

